Bupropion

Drug Profile

Bupropion

Alternative Names: 323U66; Amfebutamone; Amfebutamone SR; Aplenzin; Bupropion HCL SR; Bupropion hydrobromide; Bupropion hydrochloride; Bupropion hydrochloride SR; Bupropion XL; BVF 033; Elontril; Quomem; Wellbutrin; Wellbutrin SR; Wellbutrin XL; Wellbutrin XR; Zyban

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Biovail Corporation
  • Developer GlaxoSmithKline; Valeant Pharmaceuticals International
  • Class Antidepressants; Obesity therapies; Propiophenones; Small molecules; Smoking cessation therapies
  • Mechanism of Action Adrenergic receptor antagonists; Dopamine uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Major depressive disorder; Seasonal affective disorder; Smoking withdrawal
  • No development reported Obesity; Post-traumatic stress disorders; Social phobia

Most Recent Events

  • 17 Mar 2017 GlaxoSmithKline completes a phase III trial in Major Depressive Disorder in China (NCT02191397)
  • 15 Dec 2016 Biomarkers information updated
  • 30 Jun 2016 GlaxoSmithKline completes a phase I pharmacokinetics trial in Healthy volunteers in China (PO, Controlled release) (NCT02698553)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top